Literature DB >> 8062446

Virus production and spontaneous cell proliferation in HTLV-I-infected lymphocytes.

D L Mann1, P Martin, G Hamlin-Green, R Nalewaik, W Blattner.   

Abstract

Cultured peripheral blood lymphocytes (PBL) from HTLV-I-infected individuals proliferate in the absence of added mitogens and/or cytokines. In an attempt to answer questions regarding the activating signals for cells and virus, antibodies that react with cell surface components that are known to regulate cell activation and antibodies reacting with viral proteins were added to cultures of PBL from HTLV-I-infected, disease-free individuals. Spontaneous proliferation and virus production increased in the presence of antibodies reacting with CD3 and alpha/beta T cell receptors (TCR) while antibodies to HLA class II and viral proteins had no effect. Addition of HLA class I antibodies shut down virus production and cell proliferation. These observations indicate that both virus and cell activation may occur through the alpha/beta TCR on the infected cell. Cyclosporin A, however, markedly decreased cell proliferation but had only a modest suppressive effect on virus production. Thus, the uncoupling of cell proliferation from virus production by cyclosporin A suggests the possibility that the signal transduction pathways for these two events are different.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8062446     DOI: 10.1006/clin.1994.1147

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  11 in total

1.  Human T cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cells.

Authors:  Philip J Norris; Dale F Hirschkorn; Deborah A DeVita; Tzong-Hae Lee; Edward L Murphy
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

2.  Spontaneous cell proliferation is associated with poor sensitivity to glucocorticoids in patients infected with HTLV.

Authors:  R P Lopes; M Menna-Barreto; M E Bauer
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

3.  Autoproliferation in HIV-1-infected patients undergoing active HIV-1-specific immunotherapy.

Authors:  R J Trauger; W Giermakowska; S Wormsley; J Turner; F C Jensen; D J Carlo
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

4.  The SCHOOL of nature: IV. Learning from viruses.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-10

Review 5.  Mechanisms of T-cell activation by human T-cell lymphotropic virus type I.

Authors:  P Höllsberg
Journal:  Microbiol Mol Biol Rev       Date:  1999-06       Impact factor: 11.056

6.  Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-gamma and TGF-beta1.

Authors:  M Satoh; H Toma; Y Sato; M Takara; Y Shiroma; S Kiyuna; K Hirayama
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

7.  B-lymphocyte proliferation during bovine leukemia virus-induced persistent lymphocytosis is enhanced by T-lymphocyte-derived interleukin-2.

Authors:  E S Trueblood; W C Brown; G H Palmer; W C Davis; D M Stone; T F McElwain
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Oral administration of human T-cell leukemia virus type 1 induces immune unresponsiveness with persistent infection in adult rats.

Authors:  H Kato; Y Koya; T Ohashi; S Hanabuchi; F Takemura; M Fujii; H Tsujimoto; A Hasegawa; M Kannagi
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Increased cell proliferation, but not reduced cell death, induces lymphocytosis in bovine leukemia virus-infected sheep.

Authors:  Christophe Debacq; Becca Asquith; Pierre Kerkhofs; Daniel Portetelle; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

10.  Spontaneous proliferation of memory (CD45RO+) and naive (CD45RO-) subsets of CD4 cells and CD8 cells in human T lymphotropic virus (HTLV) infection: distinctive patterns for HTLV-I versus HTLV-II.

Authors:  H E Prince; J York; S M Owen; R B Lal
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.